Manapuram Suresh, Hashmi Hamza
Internal Medicine, Saint Francis Hospital and Medical Center, Grand Island, USA.
Oncology, University of Louisville School of Medicine, Louisville, USA.
Cureus. 2018 Dec 1;10(12):e3669. doi: 10.7759/cureus.3669.
Multiple myeloma (MM) is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. With median age of 66 at the time of presentation, multiple myeloma is predominantly a disease of the elderly. The availability of new combination regimens and the enhanced safety of autologous hematopoietic stem cell transplant has increased the treatment options for elderly patients with multiple myeloma. We provide a summary of data supporting the current management of elderly patients with newly diagnosed multiple myeloma.
多发性骨髓瘤（MM）是一种恶性浆细胞的克隆性疾病，约占血液系统恶性肿瘤的10%。多发性骨髓瘤患者确诊时的中位年龄为66岁，主要是一种老年疾病。新的联合治疗方案的出现以及自体造血干细胞移植安全性的提高，增加了老年多发性骨髓瘤患者的治疗选择。我们总结了支持当前新诊断的老年多发性骨髓瘤患者管理的数据。
